(News Bulletin 247) – Bayer today announced the initiation of a phase III study to assess the efficacy and safety of finerenone versus placebo in adults with chronic kidney disease (CKD). ) and type 1 diabetes (T1D).
The main objective of the study is to demonstrate the superiority of finerenone over placebo in reducing the urinary albumin/creatinine ratio (UACR) over 6 months.
Currently, finerenone is approved for the treatment of chronic kidney disease associated with type 2 diabetes (T2DM) in more than 70 countries worldwide.
Unlike T2D – which is primarily a chronic metabolic disease – in type 1 diabetes, the insulin-secreting cells of the pancreas are destroyed.
Therefore, ‘new strategies are needed to slow the rate of decline in kidney function, which is why this important study is good news for people with chronic kidney disease and type 1 diabetes, as well as for the clinical community,” commented Janet McGill, professor of medicine in the Division of Endocrinology, Metabolism, and Lipid Research at Washington University and co-chair of the study’s executive committee.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
